m+Medelevator.RU
← Поиск публикаций
Cell stem cell · 2026

Nanoengineered 3D culture substrate enables superior persistence and polyclonal engraftment of genetically engineered hematopoietic stem cells.

СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Midena Federico, Alessandrini Laura, Conci Claudio, Barcella Matteo, Gazzo Francesco, Jacchetti Emanuela, Carsana Edoardo, Benedicenti Fabrizio, Vacca Roberta, Della Volpe Lucrezia, Arévalo Sergio, Giannetti Kety, Barozzi Dafne, Franchino Martina, Zonari Erika, Ferrua Francesca, Farina Giacomo, Brombin Chiara, Cugnata Federica, Fiumara Martina, Tavella Teresa, Cherubin Leonardo, Fraschetta Federico, Cerullo Giulio, Osellame Roberto, Radrizzani Marina, Ferrari Samuele, Merelli Ivan, Gentner Bernhard, Scielzo Cristina, Brendolan Andrea, Naldini Luigi, Aiuti Alessandro, Montini Eugenio, Raimondi Manuela T, Di Micco Raffaella

Аннотация

Ex vivo culture of hematopoietic stem and progenitor cells (HSPCs) is required for gene therapy applications but inadvertently triggers detrimental cellular responses, potentially threatening clinical success. In this study, we employ nichoids, biocompatible 3D culture substrates with cell-scale resolution, to provide HSPCs with mechanical support during ex vivo manipulation. This innovative 3D system improves HSPC multi-lineage differentiation and engraftment capacity by leveraging mechanobiological control over nuclear morphology, cytoskeleton organization, metabolism, and DNA integrity. Notably, 3D culture enables efficient genetic engineering across multiple platforms, including long-range gene editing, base- and prime-editing, and lentiviral-mediated gene addition. Moreover, this scaffold increases the clonal output and persistence of genetically engineered cells in xenotransplantation experiments, including a clinical protocol for lentiviral gene addition in Wiskott-Aldrich syndrome. Overall, we propose a transformative approach to enhance the efficacy and safety of emerging and established hematopoietic stem cell-based gene therapy applications.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты